37 results about "Loratadine" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

The present invention relates to solid compositions. The present invention addresses the problem of providing a solid composition containing at least one substance selected from the group consisting of tepiperidine and salts thereof, and at least one substance selected from the group consisting of tranexamic acid and salts thereof, in which the dissolution of tepiperidine is improved. [Solution] A solid composition containing the following components: (A) at least one substance selected from the group consisting of tepiperidine and salts thereof; (B) at least one substance selected from the group consisting of tranexamic acid and salts thereof; and (C) at least one compound selected from the group consisting of ibuprofen and salts thereof, in which the solid composition does not include a solid composition comprising levocetirizine or loratadine.

Disclosed is a pharmaceutical composition comprising loratadine and one or more pharmaceutically acceptable excipients, fruit powders, gelling agent and other additives The additives may include buffering agenting agents, binders, stabilizing agents, solubilizing agents, colorants, sweetening agents, preservatives, coating agents, flavoring agents and diluents. The present disclosure provides for loratadine, where the buccal absorption is faster as well as the active ingredients in gum can be absorbed directly through the mucous membranes in the mouth, reducing the drawbacks of the conventional gummies which encounters the challenges of very high thermal stress of the cooking process especially where the active ingredients subject to significant chemical and / or physical degradation during the manufacturing process. The present disclosure further provides a method (100) of formulating the gummy dosage pharmaceutical composition for loratadine.

The invention discloses a loratadine oral liquid and a production process thereof. Comprising the following raw materials in parts by weight: 0.5 to 0.6 part of loratadine, 5 to 6 parts of beta-cyclodextrin, 10 to 12 parts of polyethylene glycol 400, 8 to 10 parts of glycerol, 6 to 8 parts of propylene glycol, 0.3 to 0.4 part of sucralose, 0.2 to 0.3 part of stevioside, 15 to 18 parts of maltitol, 1 to 1.2 parts of citric acid, 0.5 to 0.6 part of malic acid, 0.1 to 0.15 part of disodium EDTA (Ethylene Diamine Tetraacetic Acid), 0.8 to 1 part of vitamin C, 0.3 to 0.4 part of xanthan gum, 0.5 to 0.6 part of sodium carboxymethyl cellulose and 0.4 to 0.5 part of lemon essence. The composition comprises the following components in parts by weight: 0.1-0.15 part of menthol, 2-3 parts of hawthorn extract, 1.2-1.5 parts of soya bean lecithin and the balance of purified water, totaling 100 parts. The loratadine is clathrated by the beta-cyclodextrin, the absorption promotion effect of the soya bean lecithin is combined, and the compound sweetening agent, the compound stabilizer and the natural flavor substance are matched, so that the problems of poor solubility and obvious bitter taste of the loratadine are solved, and the stability and bioavailability of the product are also improved.

The application belongs to the field of pharmaceutical preparations and relates to a chlorpheniramine maleate liniment, which contains chlorpheniramine maleate 1 part, a cosolvent 100-140 parts, a stabilizer 12-25 parts and a binder 5-15 parts. The solubility and stability of chlorpheniramine maleate are improved, and the content of related substances in the preparation is reduced by optimizing the types and proportions of the cosolvent and the stabilizer. The full dissolution of chlorpheniramine maleate and excipients is facilitated by optimizing the preparation process, in particular the dissolution step of chlorpheniramine maleate and the stabilizer. The preparation process is simple, suitable for industrial production and convenient for market promotion.

The invention provides a loratadine tablet and a preparation process thereof. The preparation method specifically comprises the following steps: adding loratadine, lactose anhydrous and a first batch of corn starch into a wet granulator, and uniformly stirring to obtain a wet mixture; adding purified water at a certain temperature into the second batch of corn starch, uniformly stirring to form a dispersion liquid, mixing the dispersion liquid with the boiled purified water, and uniformly stirring to obtain corn starch slurry; taking the prepared corn starch slurry as an adhesive, adding the adhesive into a wet granulator, and stirring and granulating; granulating the granulated granules by using a first screen, and drying by using a fluidized bed; granulating the dried granules again by using a second screen, uniformly mixing the granules with the disintegrating agent, uniformly mixing the granules with the lubricant, and tabletting to obtain the tablet. By adopting the method provided by the invention to prepare the loratadine tablet, the problems of poor stability and high related substance content of the loratadine tablet are solved. The whole production process method is simple, efficient, low in required energy consumption, easy to operate and especially suitable for large-scale industrial production.

The invention relates to an application of loratadine in preparation of drugs for preventing and treating vascular calcification. The structural formula of the loratadine is as follows: # imgabs0. The loratadine used in the invention can significantly reduce the level of mouse aortic vascular calcification, and the experimental result proves that the loratadine has the effects of preventing and treating vascular calcification. The medicine disclosed by the invention is relatively low in toxicity and relatively high in safety.

The present application relates to a kind of HPLC-MS / MS detection method of detecting in human plasma, desloratadine and 3-hydroxydesloratadine in human plasma, it includes the following steps: (1) human plasma sample pretreatment;(2) liquid chromatography-mass spectrometry detection, using mobile phase A and mobile phase B as mixed mobile phase is carried out gradient elution, wherein: mobile phase A is methanol-acetonitrile mixed solution, in mixed solution methanol and acetonitrile volume ratio is 4-6:6-4;Mobile phase B is 2-20mM ammonium formate aqueous solution;(3) the determination of the concentration of human plasma in lopatadine, desloratadine and 3-hydroxydesloratadine.The present application uses lopatadine-d4, desloratadine-d5, 3-hydroxydesloratadine-d4 as deuterium internal standard, using Agilent, ZORBAX Eclipse XDB-Phenyl is carried out gradient elution, deuterium internal standard and the measured substance has the same retention time, chemical property and matrix effect, the reproducibility, accuracy of determining the concentration of lopatadine, desloratadine and 3-hydroxydesloratadine in plasma are good.The method of the present application can be used to evaluate the bioequivalence of lopatadine.

The present invention relates to solid compositions. The present invention addresses the problem of providing a solid composition containing ibuprofen in which changes in properties are suppressed. [Solution] A solid composition comprising the following components: (A) ibuprofen; (B) at least one substance selected from the group consisting of tepiperidine and salts thereof; and (C) at least one compound selected from the group consisting of tranexamic acid and salts thereof, in which the solid composition does not include a solid composition containing levocetirizine or loratadine.

To provide a solid composition which suppresses decline in the content of loratadine over time even when containing ibuprofen and loratadine.SOLUTION: A solid composition comprises (a) ibuprofen and (b) loratadine and further (c) at least one kind selected from the group consisting of bromhexine and salts thereof, a tranexamic acid, a glycyrrhizic acid and salts thereof, tipepidine and salts thereof, and dextromethorphan and salts thereof.SELECTED DRAWING: None

The application discloses an alcohol dehydrogenase mutant and application thereof in enzymatic synthesis of a loratadine intermediate. A plurality of alcohol dehydrogenase mutants are developed, and a loratadine chiral intermediate is obtained through an enzyme catalytic synthesis method based on the mutants, wherein the reaction condition is mild, the environment is friendly, the reaction has high regional selectivity and stereoselectivity, the reaction conversion rate is high, the chiral purity of the product is high, the enzyme consumption is low, the preparation cost is low, the method is suitable for industrial production, the method avoids the problems of difficult chiral resolution and heavy metal residue in a product in a conventional method, and the method makes up for the deficiencies of a traditional chemical method.

This invention discloses a compound ointment for protecting the nasal mucosa and repairing skin damage, and its preparation method, belonging to the field of pharmaceutical technology. The compound ointment is formulated with Sophora japonica fruit extract, erythromycin ointment, vitamin B6, levofloxacin hydrochloride tablets, loratadine tablets, fluticasone propionate nasal spray, sesame oil, and honey in specific weight proportions. The components work synergistically, providing protection for the nasal mucosa, treatment of rhinitis, reduction of cold air and external pollutant intrusion, and prevention of colds. It can also treat hemorrhoids, scars, eczema, and other skin damage, achieving "one medicine for multiple uses." This compound ointment has a stable dosage form, is convenient to use, has high utilization rate, high safety, and no obvious side effects, making it suitable for various populations and possessing good industrialization prospects.

The present invention relates to the technical field of traditional Chinese medicines, and specifically discloses a pharmaceutical composition for treating a cold and a preparation method thereof, wherein the pharmaceutical composition comprises, by weight, 10-20 parts of acetaminophen, 0.5-0.9 parts of loratadine, 240-330 parts of herba phyllanthi, 320-420 parts of herba chelidonii and 100-150 parts of herba xanthium. The pharmaceutical composition of the present invention can effectively treat various types of colds, including influenza virus, cold-type cold and heat-type cold, effectively relieve fever, prevent and treat influenza virus, and will not cause side effects of drowsiness and loss of appetite, and has a definite curative effect through the combination of traditional Chinese medicine extracts and western medicines.

1. Name of the product of this design: Pharmaceutical packaging box (loratadine orally disintegrating tablets). 2. Purpose of this design product: This design product is used for medicine packaging boxes. 3. The key design point of this design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The application relates to the technical field of pharmaceutical preparations, in particular to a loratadine immediate-release tablet based on a co-micronization technology and a preparation method thereof; a pharmaceutical composition comprises a co-micronization compound, the co-micronization compound comprises loratadine and a co-micronization carrier; the application discloses a loratadine immediate-release tablet based on a co-micronization technology and a preparation method thereof, the dissolution rate and stability of the loratadine are improved by adopting the co-micronization technology and a new type of excipient combination; meanwhile, the prepared loratadine immediate-release tablet also has good in-vitro dissolution performance; the loratadine immediate-release tablet prepared by the application reduces impurity growth in the production and storage processes and obviously improves the stability of the drug; the loratadine immediate-release tablet disclosed by the application does not contain lactose in the prescription, so that the side reaction of lactose intolerance can be effectively avoided.

The present invention provides a desloratadine orally dissolving film composition, a preparation method thereof, and applications thereof. The present invention provides a desloratadine orally dissolving film composition comprising an active drug, a film-forming material, a plasticizer, and a flavoring agent. The active drug is 8-chloro-6,11-dihydro-11-(4-piperidinyl)-5H-benzo-[5,6]heptylcyclo[1,2-b]pyridine as shown in Formula I. The desloratadine orally dissolving film composition of the present invention has a good dissolution rate, does not leave a gritty feeling after dissolving in the oral cavity, has a uniform appearance, good flexibility, does not settle during the film solution preparation process, and meets content uniformity requirements. #imgabs0#

The present invention relates to an oral solution containing loratadine, belonging to the field of pharmaceutical preparations. The oral solution of the present invention contains loratadine, a stabilizer, and a fragrance. The oral solution is prepared by stirring loratadine with hot glycerin, heating pure water to dissolve sodium methylparaben, L-tryptophan, and methylparaben, mixing the above solutions, adding sucralose and fragrance, stirring, filtering, and packaging. The oral solution prepared by the present invention has significantly improved loratadine stability, a good mouthfeel, and high medication compliance in children. The preparation process is simple, suitable for industrial production, and has wide market promotion value.

The invention relates to the technical field of biomedical analysis, in particular to a clinical steroid hormone determination method which comprises the following steps: repeatedly treating human plasma by adopting a solid-phase extraction method, using octadecylsilane bonded silica gel filler, extracting to remove endogenous steroid hormone, and obtaining a human plasma blank matrix; the method comprises the following steps: respectively preparing a steroid hormone stock solution and a loratadine internal standard solution, taking the human plasma blank matrix treated in the step 1, adding the loratadine internal standard solution, treating with a 2% formic acid solution, extracting by using an HLB solid-phase extraction column, centrifugally concentrating an eluent, redissolving for LC-MS / MS analysis, carrying out sample analysis by adopting an LC-MS / MS method, and determining the content of the loratadine in the human plasma blank matrix. And detecting in an ESI positive ionization mode. Therefore, multiple steroid hormones can be detected at the same time, the coverage concentration range is wide, endogenous interference can be effectively removed, the detection accuracy is improved, the sensitivity is high, the repeatability is good, and the method is suitable for high-throughput analysis of clinical samples.

The invention provides a desloratadine oral soluble film composition as well as a preparation method and application thereof. The present invention provides a desloratadine oral soluble film composition, which comprises an active drug, a film forming material, a plasticizer and a flavoring agent, and the active drug is 8-chloro-6, 11-dihydro-11-(4-piperidino)-5H-benzo-[5, 6] heptyl ring [1, 2-b] pyridine represented by a formula I. The desloratadine oral soluble film composition comprises a desloratadine compound, a desloratadine compound, a desloratadine compound, a desloratadine compound, a desloratadine compound, a desloratadine compound, a desloratadine compound and a The desloratadine oral soluble film composition disclosed by the invention has the advantages of good dissolution rate, no grit feeling after being dissolved in an oral cavity, uniform appearance, good flexibility, no sedimentation in a film liquid preparation process, and content uniformity meeting requirements. # imgabs0 #

The present invention relates to a renal disease treatment effect obtained by the co-administration of desloratadine, which is an antihistamine, and duloxetine, which is a serotonin reuptake inhibitor. It has been identified that, when desloratadine and duloxetine are co-administered, the formation and growth of cysts were inhibited in an ADPKD animal model, the renal function was also maintained at a normal value, liver cysts and liver fibrosis caused by ADPKD were treated, renal fibrosis was significantly treated in in vitro and animal renal fibrosis models, and, in particular, the effects were synergistically increased.

1. The name of the design product: medicine packaging box (loratadine orally disintegrating tablets). 2. The use of the design product: the design product is used for packaging loratadine orally disintegrating tablets. 3. The design points of the design product: the combination of patterns and colors. 4. The picture or photo that best indicates the design points: perspective view. 5. The design claimed contains colors.

The invention discloses a traditional Chinese medicine composition for treating pet cough and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 8-16 parts of ephedra, 5-12 parts of almond, 5-8 parts of houttuynia cordata, 2-5 parts of licorice extract, 2-5 parts of platycodon grandiflorum extract, 3-5 parts of perilla leaf, 2-4 parts of herba siegesbeckiae, 0.5-1.5 parts of almond oil, 0.5-1.5 parts of borneol, 1-2 parts of loratadine and 3-6 parts of mannitol. According to the traditional Chinese medicine composition, through the synergistic effect of various traditional Chinese medicine components and western medicine components, the comprehensive curative effect can be achieved. Traditional Chinese medicine components such as ephedra, almond and houttuynia cordata can effectively relieve cough, clear lung and reduce phlegm; western medicine components such as loratadine and a licorice extract have anti-allergic and anti-inflammatory effects and help to relieve cough caused by allergy or infection.

To provide a solid composition containing ibuprofen, the change in properties of which is suppressed. The present invention relates to a composition comprising: (A) Ibuprofen, (B) at least one selected from the group consisting of tipepidine and salts thereof, and (C) at least one selected from the group consisting of tranexamic acid and salts thereof A solid composition comprising, but excluding a solid composition comprising levocetirizine or loratadine.

The invention belongs to the technical field of chemical synthesis, and particularly discloses a preparation method of rupatadine fumarate and an intermediate compound. The preparation method comprises the following steps: S1, dissolving 4-piperidone hydrochloride and 3-(chloromethyl)-5-methylpyridine hydrochloride in an organic solvent, and performing N-alkylation reaction under the action of alkali to obtain a compound shown as a formula III; s2, the compound shown in the formula III and tricyclic ketone are subjected to a McMurry coupling reaction in an organic solvent under the action of a coupling agent system, and rupatadine is obtained; s3, enabling rupatadine and fumaric acid to react in an organic solvent to obtain rupatadine fumarate. By preparing the compound shown in the formula III, the raw material cost for preparing rupatadine by taking loratadine as a raw material is greatly reduced, the process route is shorter, the conditions are milder, the economy of the rupatadine fumarate preparation process is improved while the operation difficulty is reduced, and the preparation method has great market prospects and popularization value.

To provide a solid composition containing at least one selected from the group consisting of tipepidine and salts thereof and at least one selected from the group consisting of tranexamic acid and salts thereof, which has improved dissolution properties of tipepidine. The present invention relates to a composition comprising the following components: (A) at least one selected from the group consisting of tipepidine and salts thereof, (B) at least one selected from the group consisting of tranexamic acid and salts thereof, and (C) at least one selected from the group consisting of ibuprofen and salts thereof A solid composition comprising, but excluding a solid composition comprising levocetirizine or loratadine.

The invention belongs to the technical field of medical application, particularly discloses novel application of loratadine in a colistin synergist, and discloses a loratadine-colistin composition and a compound preparation, and the mass ratio of loratadine to colistin is (8-512): 1. The combination of the loratadine and the colistin can obviously enhance the antibacterial activity of the colistin on enterobacteriaceae bacteria, and the FICI is 0.0938-0.1563 (both less than 0.5), that is, the combination of the loratadine and the colistin shows an obvious synergistic effect. Meanwhile, the synergist can effectively reduce the use amount of the colistin, and the use amount of the colistin used independently is 4-32 times of the use amount of the loratadine and the colistin used jointly. The bactericidal composition can play a role in synergistically reversing drug resistance, the FICI is 0.0938-0.1563, and the bactericidal composition shows an obvious bactericidal effect after 2-4 hours after drug combination.

The present invention provides a nasal administration preparation, preparation method and use for treating rhinitis, and relates to the field of medical technology. Taking the total weight of the preparation as 100%, the nasal administration preparation includes the following components in weight percentage: loratadine 0.1-5%, polyethylene glycol 3-20%, penetration enhancer 0.5-1%, and the remainder is water, wherein the polyethylene glycol is selected from at least two of polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400 and polyethylene glycol 600; the penetration enhancer is selected from at least two of sodium lauryl sulfate, bile acid derivatives, taurine, hyaluronic acid, polyoxyethylene lauryl alcohol ether, 1-ephedrine, d-ephedrine, 1-pseudoephedrine, and d-pseudoephedrine. The nasal administration preparation obtained by the present invention has the characteristics of less irritation to nasal cilia, high water solubility, high bioavailability and stable preparation, and is used to treat rhinitis.

An external anti-itch and anti-allergic drug after biting of biting midges and a preparation method thereof, relate to the technical field of medicine. The drug comprises: loratadine hydrochloride 0.1%-0.3%, 5%-8% lapis alumen, menthol 0.5%-1%, camphor 0.3%-0.5%, carvacrol 0.2%-0.5%, lemon eucalyptus oil 0.3%-0.6%, glycerol 3%-5%, panthenol 2%-4%, ceramide 0.1%-0.2%, vaseline 10%-15%, lanolin 5%-8%, deionized water and an appropriate amount of preservative. The preparation method comprises oil phase preparation, water phase preparation, high-speed emulsification and low-temperature mixing. Through the synergistic effect of anti-histamine components and physical anti-itch components, the multiple effects of rapid anti-itch, swelling, anti-allergy and skin barrier repair are realized, the pH value is close to the physiological environment of the skin, it is mild and non-irritating, and it is especially suitable for children, pregnant women and sensitive skin groups.

The present invention provides a semi-solid composition comprising a gel component in an amount sufficient to provide a gel product with binding force, an antihistamine composition comprising an antihistamine agent, and a complexing agent wherein the complexing agent is capable of interacting with the antihistamine agent and forming an antihistamine complex. In one embodiment, the antihistamine agent includes diphenhydramine, cetirizine, levocetirizine, loratadine, desloratadine, fexofenadine, azelastine, bilastine, rupatadine, or a derivative, a salt, or a combination thereof.

This invention belongs to the field of oral solid dosage form technology and relates to a loratadine sustained-release capsule and its preparation method. This application provides a loratadine-containing sustained-release capsule, wherein loratadine is melt-mixed with citric acid and salicylic acid to prepare a drug-containing core, and the core is coated with a sustained-release layer, an immediate-release layer, and a protective layer. This not only effectively solves the problem of slow dissolution of loratadine in the presence of insufficient gastric acid, but also ensures uniform drug release, achieving long-lasting effects and increased efficacy.